Overview
Quanterix Q3 revenue grows 12.3% yr/yr to $40.2 mln
Adjusted EBITDA loss widens to $11.9 mln due to acquisition charges
Company achieves key integration milestones from Akoya transaction
Outlook
Quanterix reiterates 2025 revenue guidance of $130 mln to $135 mln
Company expects 2025 adjusted cash usage of $34 mln to $38 mln
Quanterix expects to achieve cash flow breakeven in 2026
Result Drivers
REVENUE GROWTH - Quanterix achieved a 12.3% increase in revenue, despite challenging market conditions
COST SYNERGIES - Achieved $67 mln in cost synergies from Akoya transaction integration, contributing to a more scalable company
ALZHEIMER'S DIAGNOSTICS - Accelerating business with positive Medicare pricing and expanding partnerships in Asia
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $40.23 mln | ||
Q3 Net Income | -$33.52 mln | ||
Q3 Basic EPS | -$0.73 | ||
Q3 Gross Profit | $17.21 mln | ||
Q3 Operating Expenses | $54.53 mln | ||
Q3 Operating Income | -$37.33 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Quanterix Corp is $6.50, about 24% above its November 7 closing price of $4.94
Press Release: ID:nBw4sj61qa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)